Why the study?
Detailed insights into the 3D structure and protein-protein interaction partners of the (pro)renin receptor could guide drug discovery across cardiorenal and oncological diseases.
Answers are grounded in this paper and cite their sources.
Insights into the 3D structure of the (pro)renin receptor may guide the development of novel antibody- and small molecule-based therapies for cardiorenal and oncological diseases.
Experimental inhibition of the (pro)renin receptor [(P)RR] is a promising therapeutic strategy in different disease models ranging from cardiorenal to oncological entities. Here, we briefly review the direct protein-protein interaction partners of the (P)RR and the plethora of distinct diseases in which the (P)RR is involved. The first structural work on the (P)RR using AlphaFold, which was recently published by Ebihara et al., is the center of this mini-review since it can mechanistically link the protein-protein interaction level with the pathophysiological level. More detailed insights into the 3D structure of the (P)RR and its interaction domains might guide drug discovery on this novel target. Finally, antibody- and small molecule-based approaches to inhibit the (P)RR are shortly discussed.
No takes yet. Share an insight, caveat, or question.
Funke‐Kaiser et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: